慢性粒-单核细胞白血病预后评分系统与合并症:一项全国性人群基础研究
该全国性人群基础研究纳入2009至2015年诊断的337例慢性粒-单核细胞白血病(CMML)患者,评估合并症并首次验证合并症指数,同时比较IPSS-R、CPSS、MDAPS与Mayo评分的预后效能。中位总生存为21.3个月,自身免疫性疾病占25%,Charlson合并症指数(CCI)的C-index最高(0.62)且是唯一与生存独立相关的合并症指数,CPSS的C-index最高(0.69)。
要点
- CMML患者中自身免疫性疾病占25%,以风湿性多肌痛和桥本甲状腺炎最常见。
- 在CCI、HCT-CI和MDS-CI中,CCI的C-index最高(0.62)且是唯一与生存独立相关的合并症指数。
- 比较IPSS-R、CPSS、MDAPS和Mayo评分,CPSS的C-index最高(0.69)。
核心结论
- 基于真实世界数据,CCI和CPSS具有最佳的预后效能,且自身免疫性疾病在CMML中占比过高。
研究设计与样本
- 全国性人群基础研究,纳入2009至2015年诊断的337例CMML患者。
主要发现
- 中位总生存为21.3个月。
- 自身免疫性疾病存在于25%的患者中,以风湿性多肌痛和桥本甲状腺炎最常见。
- 在CCI、HCT-CI和MDS-CI中,CCI的C-index最高(0.62),且是唯一在多变量分析中与生存独立相关的合并症指数。
- 比较IPSS-R、CPSS、MDAPS和Mayo评分,CPSS的C-index最高(0.69)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes in chronic myelomonocytic leukaemia (CMML) are highly variable and may be affected by comorbidity. Therefore, prognostic models and comorbidity indices are important tools to estimate survival and to guide clinicians in individualising treatment. In this nationwide population-based study, we assess comorbidities and for the first time validate comorbidity indices in CMML. We also compare the prognostic power of: the revised International Prognostic Scoring System (IPSS-R), CMML-specific prognostic scoring system (CPSS), MD Anderson Prognostic Scoring System (MDAPS) and Mayo score. In this cohort of 337 patients with CMML, diagnosed between 2009 and 2015, the median overall survival was 21·3 months. Autoimmune conditions were present in 25% of the patients, with polymyalgia rheumatica and Hashimoto's thyroiditis being most common. Of the tested comorbidity indices: the Charlson Comorbidity Index (CCI), Haematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) and Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI), CCI had the highest C-index (0·62) and was the only comorbidity index independently associated with survival in multivariable analyses. When comparing the prognostic power of the scoring systems, the CPSS had the highest C-index (0·69). In conclusion, using 'real-world' data we found that the CCI and CPSS have the best prognostic power and that autoimmune conditions are overrepresented in CMML.
引用
- Moreno Berggren D, Kjellander M, Backlund E, et al. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. Br J Haematol. 2020. PMID: 32501529. doi:10.1111/bjh.16790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。